Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

INTRODUCTION: Empagliflozin is a new, emerging oral hypoglycemic agent (OHA) which has shown significant benefits in type 2 diabetes mellitus (T2DM) patients with cardiovascular disease. In this analysis, our aim was to systematically compare the adverse drug events (ADEs) associated with a low (10 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Xia, Luo, Zu-chun, Zhai, Lu, Zhao, Wen-piao, Huang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104263/
https://www.ncbi.nlm.nih.gov/pubmed/29524188
http://dx.doi.org/10.1007/s13300-018-0399-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104263/
https://www.ncbi.nlm.nih.gov/pubmed/29524188
http://dx.doi.org/10.1007/s13300-018-0399-z

Ejemplares similares